openPR Logo
Press release

Synta Pharmaceuticals Selects Metricstream For Quality Management System

12-20-2007 06:04 PM CET | IT, New Media & Software

Press release from: MetricStream

MetricStream, Inc., the market leader in enterprise-wide Governance, Risk, Compliance (GRC) and Quality Management solutions today announced that Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions, including cancer and chronic inflammatory diseases, has selected MetricStream to streamline their training and document control processes.

Effective procedures and content management for training and control documents is vital for pharmaceutical companies following FDA cGMP regulations and guidelines. Automation of these key business processes on an integrated compliance platform will enable Synta to improve operational efficiencies, lower the cost of regulatory compliance and create a transparent environment for managing critical records, information and data. The system will be compliant with FDA 21 CFR Part 11 requirements for electronic records and information systems.

According to Rob Michael, Senior Director of IT, Synta Pharmaceuticals sought an enterprise software solution to streamline and automate their training and document management processes. After a detailed evaluation of various solutions in the market, MetricStream was selected by Synta Pharmaceuticals based on MetricStream's next-generation technology and the capability of MetricStream's platform to provide a long-term foundation for quality, regulatory and compliance management processes...

"We look forward to working closely with Synta Pharmaceuticals over the next few months through their deployment and validation of our solution" said Carl McCauley, Vice President of Sales at MetricStream. “MetricStream continues to be the preferred choice for Life Sciences companies looking to deploy quality and regulatory compliance management solutions."

Gaurav Kapoor
MetricStream, Inc.
3000 Bridge Parkway
Redwood Shores, California 94065
United States
phone: 650-620-2932
www.metricstream.com
pr@metricstream.com

About MetricStream
MetricStream is a market leader in Enterprise-wide Governance, Risk, Compliance (GRC) and Quality Solutions for global corporations. MetricStream solutions are used by leading corporations such as Pfizer, Philips, American Airlines, NASDAQ, Sandisk, BP, Entergy, Subway, Fairchild Semiconductor, Hitachi and TaylorMade-Adidas Golf in diverse industries such as Pharmaceuticals, Medical Devices, Automotive, Food, High Tech Manufacturing, Energy and Financial Services to manage their quality processes, regulatory and industry-mandated compliance and corporate governance initiatives, as well as by over a million compliance professionals worldwide via the ComplianceOnline.com portal. MetricStream is headquartered in Redwood Shores , California and can be reached at www.metricstream.com.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synta Pharmaceuticals Selects Metricstream For Quality Management System here

News-ID: 34270 • Views:

More Releases from MetricStream

UBS selects MetricStream solution for Global Internal Audit Management
UBS, a leading global financial services firm and Bangalore based MetricStream, the market leader in the enterprise-wide Governance, Risk, Compliance (GRC) and Quality Management solutions has announced that UBS has selected the MetricStream GRC platform to support its internal audit management processes. The MetricStream solution will provide UBS with a fully integrated and state-of-the-art system for managing the risk-based internal audit processes for its global operations spread over multiple countries
MetricStream to Host a Complimentary Webinar on Enabling Risk Management
MetricStream, Inc., the market leader in enterprise-wide Governance, Risk, Compliance (GRC) and Quality Management solutions, today announced that it is hosting a complimentary webinar titled “Run up to the Economic Crisis: Enabling Risk Management” on Thursday, March 5, 2008 at 9:00am Pacific (12:00pm Eastern). Interactive Session will Feature David R. Koenig, CEO of The Governance Fund, LLC and Former Chair, BoD PRMIA and will focus on approaches for restoring confidence
MetricStream Discusses Enterprise GRC Roadmap at Utilities & Energy Conference H …
MetricStream, Inc., the market leader in enterprise-wide Governance, Risk, Compliance (GRC) and Quality Management solutions, today announced that it participated in the 2009 Utilities & Energy Conference that was hosted by Society of Corporate Compliance & Ethics. The conference was held on March 1-3, 2009 at the JW Marriott Hotel, Houston, TX and focused on bringing in-depth discussion and education to GRC professionals in the utilities and energy industry. At
UBS Selects MetricStream GRC Platform for Global Internal Audit Management
Zurich, Switzerland and Palo Alto, California – UBS, a leading global financial services firm and MetricStream, Inc., the market leader in the enterprise-wide Governance, Risk, Compliance (GRC) and Quality Management solutions today announced that UBS has selected the MetricStream GRC platform to support its internal audit management processes. The MetricStream solution will provide UBS with a fully integrated and state-of-the-art system for managing the risk-based internal audit processes for its

All 5 Releases


More Releases for Synta

Epithelial Ovarian Cancer Treatment Market Segmented by Product, Top Manufacture …
Complete study of the global Epithelial Ovarian Cancer Treatment market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Epithelial Ovarian Cancer Treatment industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the
Global Oropharyngeal Cancer Diagnosis and Therapeutics Market to experience sign …
A report was recently published by Orion Market Research (OMR) on the global oropharyngeal cancer diagnosis and therapeutics market. According to OMR analysis, the global oropharyngeal cancer diagnosis and therapeutics market is estimated to grow with a high CAGR during the forecast period (2018-2023). Rising prevalence of oropharyngeal cancer has been the major factor driving the market growth. Additionally, increasing geriatric population and rising oropharyngeal cancer associated with them is
Global Lung Cancer Therapeutics to Witness Moderate Growth| Market Opportunities …
According to OMR analysis, the global lung cancer therapeutics is estimated to grow at a significant CAGR during the forecast period (2018-2023). The adoption of lung cancer drugs and innovative lung surgeries are expected to boost the global lung cancer therapeutics market. In addition, huge demand is created by rising diagnostic centres across the globe. Investment and grants from government and private players are driving the market. In addition, there
Oropharyngeal Cancer Therapeutics Market Research Report by Leading Key Players …
The global oropharyngeal cancer therapeutics market is expected to have significant growth since the pipeline for oropharyngeal cancer is growing rapidly. Also, there are no specific drugs available for the treatment of oropharyngeal cancer providing increased opportunities for the major key players. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/oropharyngeal-cancer-therapeutics-market Oral cavity tumor or oral tumor, is tumor that begins in the mouth (also known as the oral cavity). Oropharyngeal malignancy begins in the
Key Innovation of Breast Cancer Monoclonal Antibodies market growth by focusing …
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs), including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs
Global Acute Myeloid Leukemia (AML) Treatment Market US$ 1.17 Billion 2021
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. In 2017, in the United States, an estimated 21,380 people will be diagnosed with AML. The global acute myeloid leukemia treatment market expected to reach US$ 1.17 billion by 2021, growing at CAGR 15% over the forecast period 2017-2021, owing to introduction of high-priced products and strong pipeline of upcoming drugs. During